Revefenacin Impurity 4, identified by its CAS number 3001303-52-9, is a chemical compound that is typically associated with the pharmaceutical development of revefenacin, a medication used for the treatment of chronic obstructive pulmonary disease (COPD). As an impurity, it may arise during the synthesis of the primary drug substance and is important for quality control in pharmaceutical manufacturing. The characteristics of this impurity can include its molecular structure, which may feature specific functional groups that influence its chemical behavior and stability. It is essential to assess its solubility, melting point, and reactivity, as these properties can impact the overall efficacy and safety of the final pharmaceutical product. Additionally, the identification and quantification of impurities like Revefenacin Impurity 4 are critical in ensuring compliance with regulatory standards, as they can affect the drug's pharmacokinetics and potential side effects. Comprehensive analytical techniques, such as chromatography and mass spectrometry, are typically employed to characterize such impurities in drug development.

Revefenacin Impurity 4

3001303-52-9: Revefenacin Impurity 4, identified by its CAS number 3001303-52-9, is a chemical compound that is typically associated with the pharmaceutical development of revefenacin, a medication used for the treatment of chronic obstructive pulmonary disease (COPD). As an impurity, it may arise during the synthesis of the primary drug substance and is important for quality control in pharmaceutical manufacturing. The characteristics of this impurity can include its molecular structure, which may feature specific functional groups that influence its chemical behavior and stability. It is essential to assess its solubility, melting point, and reactivity, as these properties can impact the overall efficacy and safety of the final pharmaceutical product. Additionally, the identification and quantification of impurities like Revefenacin Impurity 4 are critical in ensuring compliance with regulatory standards, as they can affect the drug's pharmacokinetics and potential side effects. Comprehensive analytical techniques, such as chromatography and mass spectrometry, are typically employed to characterize such impurities in drug development.

CAS 3001303-52-9

Revefenacin Impurity 4

Revefenacin N-Oxide-1

Ref: 4Z-R-142013

Revefenacin N-Oxide-1 Impurity

Ref: ST-EA-CP-R11007